Press releasePRNewswire
Insmed
INSM · NASDAQ
$95.67+$0.38 (+0.40%)TodayMarket closed ·
Prev close $95.29
Latest news
- Press releasePRNewswire
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
- Press releasePRNewswire
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
- Press releasePRNewswire
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
- NewsVandana Singh
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
- News
Insmed Q2 2026 Earnings Call Transcript
- Press releasePRNewswire
Insmed Announces CFO Transition
- Press releasePRNewswire
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
- Press releasePRNewswire
Insmed Expands Community Impact During Fifth Annual Global Day of Good
- Press releasePRNewswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
- Press releasePRNewswire
Insmed to Present at September 2026 Investor Conferences
- Press releasePRNewswire
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
- NewsErica Kollmann
Biotech Is Booming, But These 2 Stocks Missed the Memo
- NewsPiero Cingari
S&P 500, Dow Fall as Brent Jumps 4%, SanDisk Trims Losses: Stock Market Today
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 2%; Keurig Dr Pepper Earnings Top Views
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releasePRNewswire
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
- NewsVandana Singh
Insmed Sees Sustained Gains With Inhaled Drug for Stressed Heart Functioning
- Press releasePRNewswire
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
- Press releaseGlobe Newswire
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Press releasePRNewswire
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
- NewsKaustubh Bagalkote
Why Is Nebius Stock Surging On Tuesday?
- NewsRishabh Mishra
CoreWeave, Astera Labs, Nebius Group, And Others Added To Nasdaq-100: A 'Big Deal,' Says Jim Cramer
- NewsLekha Gupta
Why Is CoreWeave Stock Soaring Friday?
- Press releasePRNewswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Press releasePRNewswire
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
- News
10 Health Care Stocks With Whale Alerts In Today's Session
- NewsNabaparna Bhattacharya
Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?
- NewsPiero Cingari
Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today
- NewsAvi Kapoor
Nasdaq Gains Over 200 Points; US Inflation Slows To 2.7%
- NewsAvi Kapoor
Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.